A Multicenter, Parallel, Randomized, Placebo (Double-blind) and Pirfenidone (Open-label) Controlled Phase III Clinical Trial Evaluating the Efficacy and Safety of HEC585 Tablets in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Latest Information Update: 01 Aug 2025
At a glance
- Drugs Yifenidone (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Therapeutic Use
- Sponsors Sunshine Lake Pharma
Most Recent Events
- 01 Aug 2025 New trial record